DOCSLIB.ORG

Impact of COVID-19-Related Disruptions to Measles

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Impact of COVID-19-Related Disruptions to Measles RESEARCH ARTICLE Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries Katy AM Gaythorpe1‡, Kaja Abbas2‡, John Huber3‡, Andromachi Karachaliou4‡, Niket Thakkar5‡, Kim Woodruff1, Xiang Li1, Susy Echeverria-Londono1, VIMC Working Group on COVID-19 Impact on Vaccine Preventable Disease, Matthew Ferrari6†, Michael L Jackson7†, Kevin McCarthy5†, T Alex Perkins3†, Caroline Trotter4†, Mark Jit2,8†* 1MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom; 2Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; 3Department of Biological Sciences, University of Notre Dame, South Bend, United States; 4Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom; 5Institute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, United States; 6Pennsylvania State University, University Park, United States; 7Kaiser Permanante Washington, Seattle, United States; 8School of Public Health, University of Hong Kong, Hong Kong SAR, China *For correspondence: [email protected] †These authors contributed equally to this work Abstract ‡These authors also contributed equally to this work Background: Childhood immunisation services have been disrupted by the COVID-19 pandemic. WHO recommends considering outbreak risk using epidemiological criteria when deciding whether Group author details: to conduct preventive vaccination campaigns during the pandemic. VIMC Working Group on COVID- Methods: We used two to three models per infection to estimate the health impact of 50% 19 Impact on Vaccine reduced routine vaccination coverage in 2020 and delay of campaign vaccination from 2020 to 2021 Preventable Disease See page 11 for measles vaccination in Bangladesh, Chad, Ethiopia, Kenya, Nigeria, and South Sudan, for meningococcal A vaccination in Burkina Faso, Chad, Niger, and Nigeria, and for yellow fever Competing interest: See vaccination in the Democratic Republic of Congo, Ghana, and Nigeria. Our counterfactual page 12 comparative scenario was sustaining immunisation services at coverage projections made prior to Funding: See page 12 COVID-19 (i.e. without any disruption). Received: 29 January 2021 Results: Reduced routine vaccination coverage in 2020 without catch-up vaccination may lead to an Accepted: 23 June 2021 increase in measles and yellow fever disease burden in the modelled countries. Delaying planned Published: 24 June 2021 campaigns in Ethiopia and Nigeria by a year may significantly increase the risk of measles outbreaks (both countries did complete their supplementary immunisation activities (SIAs) planned Reviewing editor: Talı´a for 2020). For yellow fever vaccination, delay in campaigns leads to a potential disease burden rise Malago´n, McGill University, of >1 death per 100,000 people per year until the campaigns are implemented. For meningococcal Canada A vaccination, short-term disruptions in 2020 are unlikely to have a significant impact due to the Copyright Gaythorpe et al. persistence of direct and indirect benefits from past introductory campaigns of the 1- to 29-year- This article is distributed under old population, bolstered by inclusion of the vaccine into the routine immunisation schedule the terms of the Creative accompanied by further catch-up campaigns. Commons Attribution License, Conclusions: The impact of COVID-19-related disruption to vaccination programs varies between which permits unrestricted use infections and countries. Planning and implementation of campaigns should consider country and and redistribution provided that the original author and source are infection-specific epidemiological factors and local immunity gaps worsened by the COVID-19 credited. pandemic when prioritising vaccines and strategies for catch-up vaccination. Gaythorpe, Abbas, Huber, et al. eLife 2021;10:e67023. DOI: https://doi.org/10.7554/eLife.67023 1 of 34 Research article Epidemiology and Global Health Medicine Funding: Bill and Melinda Gates Foundation and Gavi, the Vaccine Alliance. Introduction Childhood immunisation services have been disrupted by the COVID-19 pandemic in at least 68 countries during 2020 with around 80 million under 1-year-old children being affected (Nelson, 2020; Science (AAAS), 2020; UNICEF, 2020; WHO, 2020a). This has occurred for several reasons – the diversion of health care staff, facilities, and finances to deal with COVID-19 treatment and response; reluctance of individuals to bring children to be vaccinated due to fear of infection; barriers to travel due to local physical distancing measures; disruptions in vaccine supply chains; lack of personal pro- tective equipment; and decisions to stop or postpone vaccination campaigns to reduce the risk of transmission during such campaigns. The World Health Organization (WHO) issued guidance in March 2020 on immunisation activities during the COVID-19 pandemic (WHO, 2020b). The guidance recommended a temporary suspen- sion of mass vaccination campaigns, but continuation of routine immunisation services by the health systems while maintaining physical distancing and infection prevention and control measures for COVID-19. Routine immunisation was one of the most disrupted services relative to other essential health services based on a WHO pulse survey in May and June 2020 that was focused on continuity of essential health services during the COVID-19 pandemic (WHO, 2020c). WHO, UNICEF, Gavi, the Vaccine Alliance, and their partners also conducted two pulse polls in April and June 2020 to under- stand COVID-19-related disruptions to immunisation services (WHO, 2020d). Based on respondents from 82 countries, pulse polls indicated that there was widespread disruption to routine immunisa- tion services in addition to the suspension of mass vaccination campaigns. The main reasons reported for this disruption were low availability of personal protective equipment for healthcare workers, low availability of health workers, and travel restrictions. Disruptions to routine health care due to the COVID-19 pandemic are projected to increase child and maternal deaths in low-income and middle-income countries (Roberton et al., 2020). No coun- try has made a policy decision to stop routine immunisation during a COVID-19 epidemic. Risk-bene- fit analysis of countries in Africa shows routine immunisation to have far greater benefits than risks even in the context of the COVID-19 pandemic (LSHTM CMMID COVID-19 Working Group et al., 2020). Nevertheless, routine immunisation coverage has dropped in most countries (WHO, 2020d). Evidence on the health impact of suspending vaccination campaigns during the COVID-19 pan- demic is limited. Modelling indicates that both fixed post and door-to-door campaigns targeting under 5-year-old children may cause temporary minor increases in total SARS-CoV-2 infections (Hagedorn et al., 2020). However, avoiding campaigns during the local peak of SARS-CoV-2 trans- mission is key to reducing the effect size, and SARS-CoV-2 transmission during campaigns can be minimised with good personal protective equipment and limiting movement of vaccinators (Hagedorn et al., 2020). The WHO recommends that countries consider the risk of outbreaks using epidemiological criteria when deciding whether to conduct preventive vaccination campaigns during the COVID-19 pandemic, but the guidance was not based on any quantitative assessment of trans- mission risk for either COVID-19 or existing vaccine-preventable diseases (WHO, 2020e). Hence, countries need to assess the health impact of postponing vaccination campaigns, which can inform the epidemiological risk assessment for outbreaks due to campaign delays and prioritise which vaccines to use in campaigns (WHO, 2020f). The need for such assessments is greatest in low- and lower middle-income countries which generally have greater risks of vaccine-preventable disease outbreaks and limited health care resources to deal with COVID-19 epidemics. It is difficult to quantify the impact of different scenarios using only observational data, which does not give the counterfactual to what actually happened in 2020. To address this, we used transmission dynamic models to project alternative scenarios about postponing vaccination campaigns alongside disrup- tion of routine immunisation, for three pathogens with high outbreak potential and for which mass vaccination campaigns are a key delivery mode alongside routine immunisation – measles, meningo- coccal A, and yellow fever. Gaythorpe, Abbas, Huber, et al. eLife 2021;10:e67023. DOI: https://doi.org/10.7554/eLife.67023 2 of 34 Research article Epidemiology and Global Health Medicine Materials and methods Deaths and disability-adjusted life years (DALYs) due to measles, meningococcal A, and yellow fever under different routine and campaign vaccination scenarios were projected in a subset of 10 low- and lower middle-income countries over the years 2020–2030. Projections were made using previ- ously validated transmission dynamic models; we used three models for measles, two models for meningococcal A, and two models for yellow fever (summary model details are available in Table 1a-c with full model details in Appendix Section 3; a description of the key drivers of similari- ties and differences between models is given in Appendix Section 4). Guidance used by the different
Load more

Recommended publications
  • Yellow Fever Vaccine See Hojas De Información Sobre Vacunas Están Disponibles En Español Y En Muchos Otros What You Need to Know Idiomas
    VACCINE INFORMATION STATEMENT Many Vaccine Information Statements are available in Spanish and other languages. Yellow Fever Vaccine See www.immunize.org/vis Hojas de información sobre vacunas están disponibles en español y en muchos otros What You Need to Know idiomas. Visite www.immunize.org/vis 1 What is yellow fever? 3 Yellow fever vaccine Yellow fever is a serious disease caused by the yellow Yellow fever vaccine is a live, weakened virus. It is fever virus. It is found in certain parts of Africa and given as a single shot. For people who remain at risk, a South America. booster dose is recommended every 10 years. Yellow fever is spread through the bite of an infected Yellow fever vaccine may be given at the same time as mosquito. It cannot be spread person to person by direct most other vaccines. contact. Who should get yellow fever vaccine? People with yellow fever disease usually have to be • Persons 9 months through 59 years of age traveling hospitalized. Yellow fever can cause: to or living in an area where risk of yellow fever is • fever and flu-like symptoms known to exist, or traveling to a country with an entry • jaundice (yellow skin or eyes) requirement for the vaccination. • bleeding from multiple body sites • Laboratory personnel who might be exposed to yellow • liver, kidney, respiratory and other organ failure fever virus or vaccine virus. • death (20% - 50% of serious cases) Information for travelers can be found online through CDC (www.cdc.gov/travel), the World Health 2 How can I prevent yellow fever? Organization (www.who.int), and the Pan American Health Organization (www.paho.org).
    [Show full text]
  • Recombivax HB , YF-Vax – Drug Shortages
    Recombivax HB®, YF-Vax® – Drug shortages • The drug shortages of Recombivax HB (hepatitis B vaccine, recombinant) and YF-Vax (yellow fever virus strain 17d-204 live antigen) are ongoing. Recombivax HB and YF-Vax have been unavailable for at least 90 days. Product Description NDC # Recombivax HB (hepatitis B vaccine, recombinant) 0.5 mL (5 mcg) 0006-4981-00, 0006- pediatric/adolescent formulation 4093-02, 0006-4093-09 single-dose vials and prefilled syringes Recombivax HB (hepatitis B vaccine, 0006-4995-00, 0006- recombinant) 1 mL (10 mcg) adult 4995-41, 0006-4094-02, formulation single-dose vials and 0006-4094-09 prefilled syringes YF-Vax (yellow fever virus strain 17-d- 49281-0915-01, 49281- 2014 live antigen) single- and multi- 0915-05 dose vials — The shortage of Recombivax HB is due to increased global demand. — The Recombivax HB pediatric/adolescent and adult formulations are estimated to be available in the first half of 2018 and the first half of 2019, respectively. — The Recombivax HB dialysis formulation is available; however, the dose is different than the adult and pediatric/adolescent formulations. — YF-Vax is unavailable because the manufacturer, Sanofi Pasteur, is transitioning production to a new facility in 2018. YF-Vax is estimated to be available by mid-2018. • Recombivax HB is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. — Engerix-B™ (hepatitis B vaccine, recombinant) is another currently available vaccine that carries the same indication as Recombivax HB. Engerix-B is not in shortage. — Heplisav-B™ (hepatitis B vaccine, recombinant) was recently approved and carries the same indication as Recombivax HB.
    [Show full text]
  • Yellow Fever Vaccine Program Manual
    Vaccine Preventable Disease Program Yellow Fever Vaccine Program Manual New Jersey Department of Health Vaccine Preventable Disease Program P.O. Box 369 Trenton, NJ 08625 Phone 609-826-4860 Table of Contents Yellow Fever Certification ......................................................... 1 Certified Uniform Yellow Fever Stamp Holder .......................... 1 Certified Yellow Fever Vaccine Uniform Stamp ........................ 1 Who Can Apply? ...................................................................... 2 Application Requirements ........................................................ 2 Responsibilities of Uniform Stamp Holder ................................ 3 Period of Certification/Recertification ........................................ 4 Responsibilities of Yellow Fever Vaccine Coordinator .............. 4 Registries ................................................................................. 4 Change Notifications ................................................................ 5 Replacement Stamp ................................................................. 5 Standards, Recordkeeping, and Storage .................................. 5 YEL LOW FEVER VACCINE PR OGRAM Yellow Fever Certification According to International Health Regulations, yellow fever vaccine must be administered at certified yellow fever vaccination centers. Healthcare providers are authorized to administer the vaccine by state health departments and the states then report certified providers to the Centers for Disease Control and Prevention
    [Show full text]
  • Yellow Fever Vaccine
    Yellow Fever Vaccine: Current Supply Outlook UNICEF Supply Division May 2016 0 Yellow Fever Vaccine - Current Supply Outlook May 2016 This update provides revised information on yellow fever vaccine supply availability and increased demand. Despite slight improvements in availability and the return of two manufacturers from temporary suspension, a constrained yellow fever vaccine market will persist through 2017, exacerbated by current emergency outbreak response requirements. 1. Summary Yellow fever vaccine (YFV) supply through UNICEF remains constrained due to limited production capacity. Despite the return of two manufacturers from temporary suspension, the high demand currently generated from the yellow fever (YF) outbreak in Angola, in addition to potential increased outbreak response requirements in other geographic regions, outweigh supply. The demand in response to the current YF outbreak in Angola could negatively impact the supply availability for some routine immunization programme activities. UNICEF anticipates a constrained global production capacity to persist through 2017. UNICEF has long-term arrangements (LTAs) with four YFV suppliers to cover emergency stockpile, routine immunization, and preventative campaign requirements. During 2015, UNICEF increased total aggregate awards to suppliers to reach approximately 98 million doses for 2016- 2017. However, whereas supply can meet emergency stockpile and routine requirements, it is insufficient to meet all preventive campaign demands, which increased the total demand through UNICEF to 109 million doses. The weighted average price (WAP) per dose for YFV increased 7% a year on average since 2001, from US$ 0.39 to reach US$ 1.04 in 2015. Given the continued supply constraints, UNICEF anticipates a YFV WAP per dose of US$1.10 in the near-term.
    [Show full text]
  • 2021 Medicare Vaccine Coverage Part B Vs Part D
    CDPHP® Medicare Advantage Vaccine Coverage Guide Part B (Medical) vs. Part D (Pharmacy) Medicare Part B (Medical): Medicare Part D (Pharmacy): Vaccinations or inoculations Vaccinations or inoculations are included when the administration is (except influenza, pneumococcal, reasonable and necessary for the prevention of illness. and hepatitis B for members at risk) are excluded unless they are directly related to the treatment of an injury or direct exposure to a disease or condition. • Influenza Vaccine (Flu) • BCG Vaccine • Pneumococcal Vaccine • Diphtheria/Tetanus/Acellular Pertussis Vaccine (ADACEL, (Pneumovax, Prevnar 13) BOOSTRIX, DAPTACEL, INFANRIX) • Hepatitis B Vaccine • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus (Recombivax, Engerix-B) Vaccine (KINRIX, QUADRACEL) for members at moderate • Diphtheria/Tetanus Vaccine (DT, Td, TDVAX, TENIVAC) to high risk • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus Vac­ • Other vaccines when directly cine/ Haemophilus Influenzae Type B Conjugate Vaccine (PENTACEL) related to the treatment of an • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus injury or direct exposure to a Vaccine/Hepatitis B Vaccine (PEDIARIX) disease or condition, such as: • Haemophilus Influenzae Type B Conjugate Vaccine (ActHIB, PedvaxHIB, • Antivenom Sera Hiberix) • Diphtheria/Tetanus Vaccine • Hepatitis A Vaccine, Inactivated (VAQTA) (DT, Td, TDVAX, TENIVAC) • Hepatitis B Vaccine, Recombinant (ENGERIX-B, RECOMBIVAX HB) • Rabies Virus Vaccine for members at low risk (RabAvert,
    [Show full text]
  • Optimizing Vaccine Allocation for COVID-19 Vaccines Shows The
    ARTICLE https://doi.org/10.1038/s41467-021-23761-1 OPEN Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination ✉ Laura Matrajt 1 , Julia Eaton 2, Tiffany Leung 1, Dobromir Dimitrov1,3, Joshua T. Schiffer1,4,5, David A. Swan1 & Holly Janes1 1234567890():,; Most COVID-19 vaccines require two doses, however with limited vaccine supply, policy- makers are considering single-dose vaccination as an alternative strategy. Using a mathe- matical model combined with optimization algorithms, we determined optimal allocation strategies with one and two doses of vaccine under various degrees of viral transmission. Under low transmission, we show that the optimal allocation of vaccine vitally depends on the single-dose efficacy. With high single-dose efficacy, single-dose vaccination is optimal, preventing up to 22% more deaths than a strategy prioritizing two-dose vaccination for older adults. With low or moderate single-dose efficacy, mixed vaccination campaigns with com- plete coverage of older adults are optimal. However, with modest or high transmission, vaccinating older adults first with two doses is best, preventing up to 41% more deaths than a single-dose vaccination given across all adult populations. Our work suggests that it is imperative to determine the efficacy and durability of single-dose vaccines, as mixed or single-dose vaccination campaigns may have the potential to contain the pandemic much more quickly. 1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 2 School of Interdisciplinary Arts and Sciences, University of Washington, Tacoma, WA, USA. 3 Department of Applied Mathematics, University of Washington, Seattle, WA, USA.
    [Show full text]
  • The Present and Future of Yellow Fever Vaccines
    pharmaceuticals Review The Present and Future of Yellow Fever Vaccines Clairissa A. Hansen 1 and Alan D. T. Barrett 1,2,* 1 Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-4036, USA; [email protected] 2 Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX 77555-4036, USA * Correspondence: [email protected] Abstract: The disease yellow fever (YF) is prevented by a live-attenuated vaccine, termed 17D, which has been in use since the 1930s. One dose of the vaccine is thought to give lifelong (35+ years) protective immunity, and neutralizing antibodies are the correlate of protection. Despite being a vaccine-preventable disease, YF remains a major public health burden, causing an estimated 109,000 severe infections and 51,000 deaths annually. There are issues of supply and demand for the vaccine, and outbreaks in 2016 and 2018 resulted in fractional dosing of the vaccine to meet demand. The World Health Organization (WHO) has established the “Eliminate Yellow Fever Epidemics” (EYE) initiative to reduce the burden of YF over the next 10 years. As with most vaccines, the WHO has recommendations to assure the quality, safety, and efficacy of the YF vaccine. These require the use of live 17D vaccine only produced in embryonated chicken eggs, and safety evaluated in non- human primates only. Thus, any second-generation vaccines would require modification of WHO recommendations if they were to be used in endemic countries. There are multiple second-generation YF vaccine candidates in various stages of development that must be shown to be non-inferior to the current 17D vaccine in terms of safety and immunogenicity to progress through clinical trials to potential licensing.
    [Show full text]
  • Oklahoma State Department of Health 01-2018 Revised Immunization
    Oklahoma State Department of Health 01-2018 Revised IMMUNIZATION I. DEFINITION: The process whereby a person is made immune or resistant to an infectious disease. This term is often used interchangeably with vaccination or inoculation. II. CLINICAL FEATURES: (ACTIVE IMMUNITY) Results when exposure to a disease organism triggers the immune system to produce antibodies to that disease. Exposure to the disease organism can occur through infection with the actual disease (resulting in natural immunity), or introduction of a killed or weakened form of the disease organism through vaccination (vaccine-induced immunity). Active immunity is long-lasting, and sometimes life-long. III. MANAGEMENT PLAN: A. Administer immunizations provided by the health department per the most current recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease and Control (CDC). B. The PHN is to administer all immunizations due at the visit. If this does not occur, the PHN is to document the reason in the client record. The parent is to be educated on the safety concerns and issues raised by not immunizing their child as recommended. C. For Mass Clinic Administration: Do NOT prefill syringes or pre-open syringes/needles. This compromises sterility and vaccine competency. D. Immunization for International Travelers: Information concerning the specific recommendations and requirements for immunization of international travelers can be found in the Centers for Disease Control and Prevention (CDC) publication Health Information for International Travel, the “Yellow Book”. This publication may be accessed online at http://www.cdc.gov/travel/yb/index.htm. For the most current information, travelers may be referred to CDC’s website at www.cdc.gov/travel.
    [Show full text]
  • Routine Immunizations
    Drug and Biologic Coverage Policy Effective Date ............................................... 7/1/2021 Next Review Date ......................................... 4/1/2022 Coverage Policy Number .................................. 9001 Routine Immunizations Table of Contents Related Coverage Resources Coverage Policy ................................................... 1 Preventive Care Services General Background ............................................ 2 Covid-19 Vaccine Coding/Billing Information .................................... 3 References .......................................................... 7 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event
    [Show full text]
  • Evaluation and Management of Adverse Reactions to Vaccines John M Kelso, MD
    Evaluation and Management of Adverse Reactions to Vaccines John M Kelso, MD Division of Allergy, Asthma and Immunology Scripps Clinic San Diego CA Clinical Professor of Pediatrics and Internal Medicine University of California, San Diego School of Medicine Faculty Disclosure Information • I have not had a significant financial interest or other relationship with the manufacturers of the products or providers of the services that will be discussed in my presentation. • This presentation will not include discussion of pharmaceuticals or devices that have not been approved by the FDA. Objectives • Appreciate the nature of IgE-mediated and non-IgE- mediated adverse reactions to various vaccines. • Appropriately refer patients who have had adverse reaction to vaccines. • Provide advice to patients regarding the future administration of vaccines after an adverse reaction to a previously administered vaccine. Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012; 130:25-43. Dreskin SC, Halsey NA, Kelso JM, et al. International Consensus (ICON): allergic reactions to vaccines. WAO Journal 2016;9:1-21. Common Reactions Mild local (injection site) reactions and constitutional symptoms, such as fever, after vaccinations are common and do not contraindicate future doses. Delayed Type Hypersensitivity Rarely, delayed-type hypersensitivity (DTH) to a vaccine constituent, such as neomycin or thimerosal, may cause a temporary injection site nodule, but DTH to these constituents, or a history of such nodules is not a contraindication to subsequent vaccination. Anaphylaxis Anaphylactic reactions to vaccines are estimated to occur at a rate of approximately 1 per million doses.
    [Show full text]
  • Yellow Fever Virus and Yellow Fever Vaccine Likelihood of Secondary Transmission: • Unlikely If Mosquito Access to Infected Individuals Is Disease Agent: Prevented
    Yellow Fever Virus and Yellow Fever Vaccine Likelihood of Secondary Transmission: • Unlikely if mosquito access to infected individuals is Disease Agent: prevented. • Yellow fever virus (YFV) • Transmission of YF 17D vaccine virus from recently immu- nized donors to recipients and through breast milk has Disease Agent Characteristics: been reported. • Family: Flaviviridae; genus Flavivirus At-Risk Populations: • Morphology: Enveloped, spherical, particles 50 nm in diam- eter with icosahedral nucleocapsid symmetry and surface • Unvaccinated and other nonimmune individuals in endemic projections; virions contain three structural proteins, C, E and epidemic areas. These might include forestry workers, (the major envelope protein) and either prM in immature oil field workers and agricultural workers in forests where virions or M in mature virions and seven non-structural pro- YFV may be found, military personnel, travelers, and people teins. There are seven genotypes. in urban settings where YFV has been introduced. • Nucleic acid: Linear, positive-sense, single-stranded RNA, Vectors and Reservoir Involved: ~11 kb long • Physicochemical properties: Virions are stable at slightly • An urban cycle of YFV is accomplished via Aedes aegypti mos- alkaline pH 8.0 and low temperatures (particularly at -60°C quitoes. The extrinsic incubation period in the urban vector and below), readily inactivated at acidic pH (<4.0), tempera- is ~10 days (range, 2-37 days). The sylvatic (rural or jungle) tures equal to or above 56°C for 30 min, in organic solvents, cycle depends on the presence of other Aedes spp. and other detergents, ultraviolet light, gamma irradiation, and various mosquito species, such as Haemagogus. YFV is maintained in disinfectants.
    [Show full text]
  • Spotlight the HPV Vaccine Is Cancer Prevention the Upshot Got News
    Spotlight The Upshot The HPV Vaccine is Cancer Prevention Important news, special events, and helpful resources about how Each year, more than 11,000 women in the United States get immunizations can protect you cervical cancer. January is Cervical Health Awareness Month, and your loved ones. and you should know that there’s a lot you can do to prevent cervical cancer. Learn more by clicking the following links: Got News? #Us vs. HPV: Webinar Series Interested in sharing information The American Cancer Society’s about relevant news, events, HPV Survivor Videos and resources? CDC HPV Information page Contact Us One Million Adults Say Yes Facts & Finds to ImmTrac2 Do I need the flu More than one million adult immunization records vaccine? will remain accessible in the Texas Immunization Read More Registry. Influenza activity is increasing in Dr. Lori Anderson Named HPV Texas. Vaccine is Cancer Read More Prevention Champion Traveling soon? Congratulations to Dr. Lori Anderson for Get the vaccines being selected as the 2018 HPV Vaccine you need. Is Cancer Prevention Champion Read More award recipient for Texas. Events Yellow Fever Vaccine Update Yellow Fever is a disease spread by mosquito bites. The Yellow fever vaccine is the best protection against the disease. The Journey of your Child's Vaccines Explore the how the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and Advisory Committee on Immunization Practices (ACIP) work together to bring vaccines to you. Misconceptions About the Flu Why do some people not feel well after getting the seasonal flu vaccine? In the heart of flu season, it's important to know the truth regarding common misconceptions about the flu.
    [Show full text]